A federal trial judge has approved the national settlement of a multidistrict litigation class action alleging that the generic version of the popular antidepressant drug Wellbutrin was not as therapeutically effective as the brand-name drug. He also took a shot at a landmark U.S. Supreme Court decision in the process.
The drugmakers agreed to give injunctive relief to the class by changing their product labels and taking other measures that the plaintiffs say will protect consumers. A total of $4.5 million in attorney fees and class counsel costs also was approved.
